SPRY — ARS Pharmaceuticals, Inc. Stock Price, Chart & AI Report

Positive Nov 10, 2025 • 11:00 UTC GlobeNewswire Inc. • Ars Pharmaceuticals

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

ARS Pharmaceuticals reported $32.5 million in revenue for Q3 2025, primarily from neffy epinephrine nasal spray sales. The company continues to expand market presence through direct-to-consumer campaigns and has strong cash reserves of $288.2 million.

SPRY ALFRY MD epinephrine nasal spray anaphylaxis pharmaceutical medical device

Sentiment note

Strong revenue growth, expanding product market share, successful direct-to-consumer campaigns, and substantial cash reserves indicate positive business performance

Neutral Aug 13, 2025 • 19:04 UTC The Motley Fool • Jesterai

ARS Pharma Sales Jump 3,040% in Q2

ARS Pharmaceuticals reported strong Q2 2025 revenue of $15.7 million, driven by its needle-free epinephrine nasal spray neffy. Prescription volumes grew 180%, and commercial coverage reached 93%, though high operating costs led to a net loss of $44.9 million.

SPRY epinephrine nasal spray allergic reactions pharmaceutical commercialization

Sentiment note

Mixed performance with strong revenue growth and product adoption, but offset by significant operating expenses and net loss

Positive Jan 6, 2025 • 13:00 UTC GlobeNewswire Inc. • N/A

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

ARS Pharmaceuticals has filed for approval of its epinephrine nasal spray 'neffy' in Canada and the United Kingdom, where it will be marketed as 'EURneffy', on behalf of its licensing partner ALK-Abelló A/S. The filing is part of the company's efforts to expand the global availability of this life-saving treatment for severe allergic reactions.

SPRY ARS Pharmaceuticals neffy epinephrine nasal spray ALK-Abelló A/S Canada United Kingdom

Sentiment note

The article highlights ARS Pharmaceuticals' efforts to expand the global availability of its epinephrine nasal spray 'neffy', which is indicated for the emergency treatment of severe allergic reactions. The company's filing for approval in Canada and the UK, as well as its existing licensing partnerships in other regions, suggest a positive outlook for the company's growth and the potential impact of its product.

Positive Dec 13, 2024 • 21:58 UTC GlobeNewswire Inc. • N/A

ARSファーマシューティカルズ (ARS Pharmaceuticals)、neffy®の中国、日本、オーストラリアでの承認申請を発表

ARS Pharmaceuticals announced that its licensing partners in China, Japan, and Australia have filed for regulatory approval of its epinephrine nasal spray, neffy, for the treatment of type I allergic reactions including anaphylaxis. The company is focused on making this life-saving treatment widely available globally.

SPRY ARS Pharmaceuticals neffy epinephrine nasal spray anaphylaxis type I allergic reactions

Sentiment note

The article highlights ARS Pharmaceuticals' efforts to make its life-saving epinephrine nasal spray, neffy, available globally through regulatory filings in multiple countries. This suggests the company is proactively working to expand access to its innovative product.

Positive Dec 13, 2024 • 21:58 UTC GlobeNewswire Inc. • Ars Pharmaceuticals, Inc.

ARS Pharmaceuticals 宣布在中国、日本和澳大利亚申请批准 neffy®

ARS Pharmaceuticals, a biopharmaceutical company, announced that its authorized partners in China, Japan, and Australia have submitted applications for the approval of the 2 mg dose of neffy, its epinephrine nasal spray, in their respective countries. The 2 mg dose of neffy was recently approved in the US for the treatment of type I allergic reactions, including anaphylaxis, in adults and children weighing at least 30 kg.

SPRY ARS Pharmaceuticals neffy epinephrine nasal spray type I allergic reactions anaphylaxis

Sentiment note

The article highlights the company's efforts to expand the availability of its life-saving product, neffy, in key international markets, which suggests a positive outlook for the company's growth and impact.

Positive Dec 12, 2024 • 19:32 UTC GlobeNewswire Inc. • Ars Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

ARS Pharmaceuticals' licensing partners in China, Japan, and Australia have filed for approval of their epinephrine nasal spray 'neffy' 2 mg with regulatory agencies in their respective countries. The product has already been approved in the U.S. and EU for the emergency treatment of severe allergic reactions.

SPRY epinephrine nasal spray anaphylaxis allergic reactions regulatory approval

Sentiment note

The article highlights ARS Pharmaceuticals' efforts to make their life-saving epinephrine nasal spray 'neffy' available globally, with their licensing partners filing for regulatory approvals in key Asia Pacific markets. This suggests the company is actively working to expand the product's reach and availability.

Positive Nov 6, 2024 • 15:00 UTC GlobeNewswire Inc. • Globe Newswire

The Physician-Patient Alliance for Health & Safety Expands Board of Advisors with Five Healthcare Industry Leaders, Enhancing Commitment to Patient Safety and Innovation

The Physician-Patient Alliance for Health and Safety (PPAHS) has welcomed five new members to its Board of Advisors, bringing diverse expertise from various healthcare sectors. The new members are expected to enhance PPAHS's commitment to patient safety and innovation.

SPRY ANTM ABBV Physician-Patient Alliance for Health & Safety patient safety healthcare innovation Board of Advisors

Sentiment note

ARS Pharmaceuticals, where one of the new board members serves as Vice President and Head of Medical Affairs, has broadened access to innovative treatments such as needle-free therapies that minimize risk and fear around medication administration, which supports PPAHS's focus on patient safety.

Positive Oct 14, 2024 • 19:18 UTC Benzinga • Zacks

ARS Pharmaceuticals, Inc. is on the Move, Here's Why the Trend Could be Sustainable

ARS Pharmaceuticals (SPRY) has seen a significant price increase over the past 12 weeks, indicating a positive trend. The company's fundamentals, including a Zacks Rank #2 (Buy) and positive earnings estimate revisions, suggest the trend could be sustainable.

SPRY ARS Pharmaceuticals price trend fundamentals earnings estimate revisions

Sentiment note

The article highlights that ARS Pharmaceuticals has seen a 37.8% price increase over the past 12 weeks, indicating a positive trend. Additionally, the company's fundamentals, including a Zacks Rank #2 (Buy) and positive earnings estimate revisions, suggest the trend could be sustainable.

Positive Aug 7, 2024 • 13:01 UTC GlobeNewswire Inc. • N/A

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

ARS Pharmaceuticals, a biopharmaceutical company, announced its participation in the 2024 Wedbush PacGrow Healthcare Conference. The company is developing an intranasal epinephrine product for patients with severe allergic reactions that could lead to anaphylaxis.

SPRY ARS Pharmaceuticals Wedbush PacGrow Healthcare Conference intranasal epinephrine severe allergic reactions anaphylaxis

Sentiment note

The article highlights ARS Pharmaceuticals' participation in an upcoming healthcare conference, which suggests the company is actively engaged in its business activities and development of its intranasal epinephrine product. This indicates a positive sentiment towards the company's prospects.

Unknown Jun 28, 2024 • 10:30 UTC GlobeNewswire Inc. • ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy positioned to be the first and only needle-free adrenaline option authorized for emergency treatment of allergic reactions (anaphylaxis) in Europe

SPRY Health Product / Services Announcement

Unknown Apr 30, 2024 • 13:01 UTC GlobeNewswire Inc. • ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024

SPRY Health Licensing Agreements

Unknown Apr 3, 2024 • 13:01 UTC GlobeNewswire Inc. • ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that it has submitted its response to the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for neffy® (epinephrine nasal spray), for the treatment of Type I allergic reactions including anaphylaxis.

SPRY Health Product / Services Announcement